The use and utility of toolkits in supporting cabotegravir plus rilpivirine long-acting implementation in the CARISEL (Cabotegravir And Rilpivirine Implementation Study in European Locations) study

被引：0
|
作者：
Trehan, Rekha [1 ]
Gutner, Cassidy [2 ]
Okoli, Chinyere [1 ]
Ghosn, Jade [3 ]
Vera, Francisco [4 ]
Florence, Eric [5 ]
Lutz, Thomas [6 ]
van der Valk, Marc [7 ,8 ]
Czarnogorski, Maggie [2 ]
机构：
[1] ViiV Healthcare, Brentford, England
[2] ViiV Healthcare, Durham, NC USA
[3] Univ Paris, Paris, France
[4] Hosp Gen Univ Santa Lucia, Murcia, Spain
[5] Inst Trop Geneeskunde, Antwerp, Belgium
[6] Infekt Res, Frankfurt, Germany
[7] Univ Amsterdam, Amsterdam, Netherlands
[8] Amsterdam Inst Infect & Immun, Amsterdam, Netherlands
来源：
HIV MEDICINE | 2023年 / 24卷
关键词：
D O I：
暂无
中图分类号：
R51 [传染病];
学科分类号：
100401 ;
摘要：
P111
引用
收藏
页码：93 / 93
页数：1
相关论文
共 50 条
  • [21] Appropriateness of virological monitoring with long-acting injectable cabotegravir and rilpivirine
    Ripamonti, Diego
    Borghetti, Alberto
    Zazzi, Maurizio
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2024, 79 (10) : 2720 - 2724
  • [22] Long-Acting Cabotegravir and Rilpivirine: Innovation, New Challenges, and Opportunities
    Llibre, Josep M.
    Kuritzkes, Daniel A. R.
    CLINICAL INFECTIOUS DISEASES, 2023, 76 (09) : 1655 - 1657
  • [23] Use of long-acting injectable cabotegravir/rilpivirine in people with HIV and adherence challenges
    Christopoulos, Katerina A.
    Hickey, Matthew D.
    Rana, Aadia
    CURRENT OPINION IN HIV AND AIDS, 2025, 20 (01) : 11 - 18
  • [24] Perspectives of healthcare providers on implementation of long-acting cabotegravir plus rilpivirine in US healthcare settings from a Hybrid III Implementation-effectiveness study (CUSTOMIZE)
    Czarnogorski, Maggie
    Garris, Cindy P.
    Dalessandro, Marybeth
    D'Amico, Ronald
    Nwafor, Toyin
    Williams, Will
    Merrill, Deanna
    Wang, YuanYuan
    Stassek, Larissa
    Wohlfeiler, Michael B.
    Sinclair, Gary I.
    Mena, Leandro A.
    Thedinger, Blair
    Flamm, Jason A.
    Benson, Paul
    Spreen, William R.
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2022, 25 (09)
  • [25] Acceptability of Long-Acting Cabotegravir plus Rilpivirine in a Large, Urban, Ambulatory HIV Clinic
    Luc, Casey Morgan
    Max, Blake
    Perez, Sarah
    Herrera, Kara
    Huhn, Gregory
    Dworkin, Mark S.
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2024, 97 (04) : 409 - 415
  • [26] Expanded Insights From a Case Study on Long-Acting Injectable Cabotegravir and Rilpivirine in Pregnancy
    Ziemba, Lauren
    Ketchum, Rachel
    Brummel, Sean
    CLINICAL INFECTIOUS DISEASES, 2025,
  • [27] Therapeutic review of cabotegravir/rilpivirine long-acting antiretroviral injectable and implementation considerations at an HIV specialty clinic
    Howe, Zach W.
    Norman, Sarah
    Lueken, Abbie F.
    Huesgen, Emily
    Farmer, Eric K.
    Jarrell, Kaitlyn
    Mathis, Joscelyn E.
    Bonham, Kyle W.
    Hahn, Julie
    PHARMACOTHERAPY, 2021, 41 (08): : 686 - 699
  • [28] Cost-utility analysis of long-acting cabotegravir plus rilpivirine for the treatment of HIV infection in the United Kingdom
    Parker, B.
    Chounta, V.
    Gait, C.
    Hayward, O.
    Hunjan, M.
    Schroeder, M.
    Jacob, I.
    Van de Velde, N.
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2020, 23 : 37 - 37
  • [29] Long-acting cabotegravir plus rilpivirine for HIV treatment: FLAIR week 96 results
    Orkin, C.
    Oka, S.
    Philibert, P.
    Brinson, C.
    Bassa, A. C.
    Gusev, D.
    Degen, O.
    Gonzalez Garcia, J.
    D'Amico, R.
    Dorey, D.
    Griffith, S.
    Margolis, D. A.
    St Clair, M.
    Williams, P.
    Spreen, W. R.
    HIV MEDICINE, 2020, 21 : 14 - 14
  • [30] Uptake and discontinuation of the long-acting duo in the Swiss HIV Cohort Study: Preliminary analysis on cabotegravir plus rilpivirine
    Ramirez, J. J. Duran
    Kusejko, K.
    Metzner, K. J.
    Huber, M.
    Martin, Y.
    Stockle, M.
    Calmy, A.
    Decosterd, L. A.
    Cavassini, M.
    Bernasconi, E.
    Schmid, P.
    Gunthard, H. F.
    Braun, D. L.
    HIV MEDICINE, 2023, 24 : 79 - 81
12345